IQM Quantum Computers to Deliver Quantum Processing Units for the First Spanish Quantum Computer
6.3.2023 12:00:00 EET | Business Wire | Press release
IQM Quantum Computers (IQM), the European leader in quantum computers, announced today it has been selected to deliver quantum processing units for the first Spanish quantum computer to be installed at the Barcelona Supercomputing Center (BSC) and integrated into the MareNostrum 5 supercomputer, the most powerful in Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005345/en/
IQM Quantum Computer opened (Photo: Business Wire)
IQM is a member of the consortium led by Spanish companies Qilimanjaro Quantum Tech and GMV that was selected by Quantum Spain, an initiative promoted by the Ministry of Economic Affairs and Digital Transformation through the Secretary of State for Digitalisation and Artificial Intelligence (SEDIA) in December 2022, to build the first quantum computer for public use in Southern Europe.
Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said, “This is a significant announcement for IQM. We have the right background and experience in developing quantum processors, computers, and national quantum ecosystems. We are looking forward to working with Qilimanjaro Quantum Tech and are delighted to be part of such a strong consortium and play an important role by providing quantum processing units for this notable project.”
The integration of the quantum computer into MareNostrum 5 will have the potential to significantly increase the impact of research and innovation by enabling solutions that complement the capabilities of existing supercomputers, which will be available to the research community, companies, and public organisations, and by strengthening technological and industrial development in Spain and the creation of highly qualified jobs.
“We are delighted to include the expertise of a great player such as IQM to support us developing this innovative system, that will be purely based on Spanish and European technology. We are sure that this will be a very fruitful collaboration and we are looking forward to be partnering with IQM,” said Victor Canivell, Co-founder and CEO of Qilimanjaro.
Jani Heikkinen, Head of Business Development and Country Manager for Spain, said, “This is another example of our European leadership, demonstrating our commitment to advancing the Spanish quantum ecosystem in collaboration with both public and private institutions. Through our office in Madrid, we are also able to provide the necessary support for this project.”
About IQM Quantum Computers
IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 240 employees with offices in Singapore, Paris, Madrid, Munich, and Espoo.
About Qilimanjaro
Qilimanjaro Quantum Tech is a deep-tech startup that brings practical applications of quantum computing to the market in a shorter timeframe than digital quantum computers, by using a different but complementary model of quantum computation: the analog model.
Qilimanjaro creates a coherent quantum annealer accessible via our cloud to run real-world applications such as optimisation tasks in the logistics, finance, and energy sector, among others, and quantum simulation of chemical and physical processes, very present in the materials and pharmaceutical research industries. Qilimanjaro aims at providing its clients with a faster, more accurate and sustainable solution to their computing problems.
It has closed significant customer contracts since its first year of operation and has become a key contributor to the European Commission’s AVaQus H2020 project on coherent quantum annealing. Qilimanjaro is a spin-off from the Barcelona Supercomputer Center (BSC), the University of Barcelona (UB) and the Institute of High-Energy Physics (IFAE).
About GMV
GMV is a privately owned technology business group founded in 1984 and trading on a worldwide scale in the following sectors: Space, Aeronautics, Defense and Security, Cybersecurity, Intelligent Transportation Systems, Automotive, Healthcare, Telecommunications and IT for government authorities and major corporations. In 2021, it had revenues of nearly 260 million euros. Working with a staff of over 3,000, the company now runs subsidiaries in Spain, USA, Germany, France, Poland, Portugal, Romania, UK, The Netherlands, Belgium, Malaysia, and Colombia. Seventy five percent of its turnover comes from international projects on all five continents. The company's growth strategy is based on continuous innovation, and it plows back 5% of its turnover into inhouse R&D. GMV has reached CMMI level 5, the world's most prestigious model in terms of enhancing an organization’s process capability, and it has numerous international patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005345/en/
Contact information
IQM Media Contact
Raghunath Koduvayur, Head of Marketing and Communications
Email: Raghunath@meetiqm.com
Mobile: +65 9353 0048
www.meetiqm.com
Media Contact
Alícia Labián Pagès, Corporate Operations Manager
Email: alicia.labian@qilimanjaro.tech
Mobile: +34 676 683 876
www.qilimanjaro.tech
For more information, please contact:
marketing@gmv.com
www.gmv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom